Pfizer and Moderna Building case Support the third injection of their respective Covid-19 vaccines, but when such plans are announced Boosters starting next month, Federal health officials pointed to real-world data from ongoing research that is independent of company research. These studies indicate that the effectiveness of vaccines has declined, and this decline is more pronounced in the face of the spread of highly spread delta variants.
The research cited by federal officials covers elderly people in nursing homes, clinicians on the frontline of the pandemic, and vaccinated adults. The information is stored in state databases. Studies have shown that authorized vaccines continue to be in good condition to prevent people from suffering from serious diseases that require hospitalization. But surgeon Vivek Murthy pointed out that protection from mild and moderate diseases has declined.
“Although this new data confirms that the vaccine’s protection against the worst outcome of Covid is still high, we are worried that the decline pattern we are seeing will continue in the coming months, which may lead to serious illnesses, hospitalizations, and deaths. Protection is reduced,” Murti said at a media conference on Wednesday. “That’s why today we announced our plan to stay ahead of this virus.”
Federal health officials plan to provide booster shots for those who reach the eight-month mark after the second initial immunization from September 20.The decision was made less than a week later FDA authorizes booster injections for people with weakened immune systems, Such as organ transplant recipients and cancer patients. So far, the program to provide boosters for all vaccinated people only covers messenger RNA vaccines from Pfizer/BioNTech and Moderna. Murthy said he expects the Johnson & Johnson vaccine will also need a booster, which was developed in a single shot. The research is ongoing, and Murthy expects the data to be available in the next few weeks.
The booster shooting has not yet been completed. The plan still requires the FDA to conduct an independent evaluation of the safety and effectiveness of the third dose of the mRNA vaccine. Murthy said that the CDC’s Immunization Practice Advisory Committee will also review the evidence and issue recommendations for enhanced doses.
The World Health Organization is critical of the booster program. In another press conference, Bruce Aylward, a senior adviser to the WHO Director-General, said that vaccinating people who have not been vaccinated can save more lives than vaccinating people who have already been vaccinated with a third shot. Aylward said that COVAX is an initiative to provide Covid vaccines worldwide, but there is not enough vaccine supply yet. He added that at the same time, one country’s move to provide boosters will cause other countries to follow suit.
WHO Chief Scientist Soumya Swaminathan said that the data proves that the authorization of immunocompromised patients is necessary, and these data show that boosters can help increase antibody levels. However, if all high-income countries decide to provide boosters to people 50 years and older, it will require nearly 1 billion more vaccine doses, Swaminathan said.
“Once you start a plan like this, it’s difficult to take a step back,” she said. “In terms of science, the right thing to do now is to wait for science to tell us when a booster is needed, which populations and which vaccines need boosters. The second argument is a moral and ethical argument, that is, when people are already well protected. Give them a third dose, and the rest of the world is waiting for their primary immunization.”
Rochelle Varensky, director of the US Centers for Disease Control and Prevention, said that the United States has data to support the third dose.The state-level data she cited comes from New York Studies This is done by analyzing four databases containing vaccination and case information. The vaccine’s ability to prevent infection dropped from 91.7% when the study began on May 3 to 79.8% on July 25. Studies have shown that the decline in effectiveness against new Covid-19 cases coincides with the increase in delta variants.
Limitations of the New York data include the exclusion of some vaccinated individuals and the lack of classification of vaccine products. The study also pointed out that there is insufficient data to reliably estimate vaccine effectiveness in Covid-related deaths.
This Nursing home data Compiled from 85,593 weekly reports from 14,917 facilities. In March, the vaccine’s effectiveness was 75%. As of August 1, the effectiveness has dropped to 53%. The effectiveness of the Pfizer/BioNTech vaccine is estimated to be similar to Moderna’s. However, the study stated that although the effectiveness of both vaccines declined after the delta strain became dominant, the analysis did not distinguish between symptomatic and asymptomatic manifestations of the disease. In addition, the nursing home study did not distinguish between vaccine products and did not consider variables that may affect the effectiveness of the vaccine, such as age or underlying health status. Although effective early after the introduction of the vaccine, with the spread of delta in recent months, the decline in effectiveness has led the authors to conclude that “may consider increasing the dose for residents of nursing homes and long-term care facilities to optimize the protective immune response. “
Varensky also pointed to preliminary data from two vaccine effectiveness studies, including more than 4,000 medical staff, first responders, and other frontline workers in eight locations across the country. She said these data show that the effectiveness of symptomatic and asymptomatic infections has dropped from 92% before delta variants appeared to 64% of delta.
Jeff Zients, the White House’s director of Covid-19 response, said that when boosters are available, they will be provided free of charge, regardless of insurance or immigration status. He added that the United States has shipped more than 115 million doses of vaccine to 80 countries, and the government will continue to support global vaccination efforts. These plans include increasing manufacturing output in the United States and overseas.
“Our wartime efforts will continue to do our best to get more people vaccinated at home and around the world,” Zients said. “We can and must do both at the same time, because that is all we need to end this pandemic.”
COVAX has set up a Target 2 billion doses will be delivered by the end of 2021. As of Wednesday evening, the organization’s website stated that about 208 million doses have been shipped so far.
Image: appledesign, Getty Images
